Navigation Links
Leukemia Drug Breakthrough Study In New England Journal Of Medicine

Alan List, M.D., leader of the Hematologic Malignancies Program at the H. Lee Moffitt Cancer Center & Research Institute, recently conducted a phase I/II trial of the experimental drug Revlimid showing promise as an innovative way to treat patients with myelodysplastic syndrome (MDS), a form of pre-leukemia. Given in pill form, Revlimid simultaneously blocks the growth of new blood vessels that nourish tumors (anti-angiogenesis) and stimulates the immune system to fight cancer cells. The study is reported in the Feb.10 issue of the New England Journal of Medicine.

Nearly 90 percent of MDS patients are anemic and require regular transfusions of red cells. In this study, 91 percent of the MDS patients with a chromosome abnormality named 5q minus syndrome became transfusion independent. The defective 5q chromosome abnormality may be linked to other serious cancers, including leukemias and small cell lung cancer.

In another finding of the same study, all the patients with the 5q deletion who became transfusion independent also went into cytogenetic remission, meaning that the chromosome abnormality disappeared.

List, a professor of interdisciplinary oncology at the University of South Florida, initially developed the phase I clinical trial of Revlimid for treatment of MDS following his laboratory observations that the agent improved the growth of red blood cell precursors from MDS bone marrow. Celgene will submit the seminal findings of List's phase I trial - along with data from two recent confirmatory phase II clinical trials performed nationwide involving more than 350 patients with red blood cell transfusion-dependent MDS - to the U.S. Food and Drug Administration in a new drug application (NDA) for Revlimid as an innovative approach to treat the anemia of MDS patients with the 5q minus deletion.

In 2001, the National Cancer Institute awarded Moffitt the status of a Comprehensive Cancer Center in recognition of its excellence in re
'"/>

Source:University Of South Florida Health Sciences Center


Page: 1 2

Related biology news :

1. Protein That Promotes Survival Of Stem Cells Might Be Key To Poor Leukemia Prognosis
2. Genetically Modified Natural Killer Immune Cells Attack, Kill Leukemia Cells
3. Loosen up, DNA: Leukemia gene changes genetic packaging
4. Leukemia drug turns mini-molecules up, cancer genes down
5. Breakthrough Microarray-based Technology for the Study of Cancer
6. Breakthrough method in nanoparticle synthesis paves the way for new pharmaceutical and biomedical applications
7. Breakthrough isolating embryo-quality stem cells from blood
8. Breakthrough System for Understanding Ocean Plant Life Announced
9. Breakthrough: Scientists create worlds tiniest organic particles
10. Breakthrough in micro-device fabrication combines biology and synthetic chemistry
11. Sciences Breakthrough of the Year: Watching evolution in action
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Leukemia Drug Breakthrough Study New England Journal Medicine

(Date:7/11/2014)... University of Chicago is creating a new professorship ... the University,s Institute for Molecular Engineering and the ... donation from the Millicent and Eugene Bell Foundation., ... reside within the Institute for Molecular Engineering. That ... project at the MBL,s Eugene Bell Center for ...
(Date:7/11/2014)... "mouse TRAP" to capture the early signs of kidney ... the Journal of Clinical Investigation . Their new ... extract cellular and genetic information from a variety of ... Institute for Medical Research in 2008, TRAP involves attaching ... of the cell type of interest. Scientists can then ...
(Date:7/11/2014)... 10, 2014---A team of researchers from The Chinese University ... a gene of wild soybean linked to salt tolerance, ... in saline soil. This study published online in ... novel genomic information for crop improvement. , Soybean is ... and human selection, cultivated soybeans have less genetic diversities ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2BGI reports a novel gene for salt tolerance found in wild soybean 2
... Richfield Co. was tasked with cleaning up a major superfund ... Texas A&M University professor, got a call to assist the ... crop science professor, spent two years leading a Texas A&M ... of copper mining, mineral processing and smelting in the Anaconda, ...
... In the first side-by-side tests of a half-dozen palladium- and ... scientists have found that palladium destroys TCE far faster than ... cases. The results will appear in a new study ... B: Environmental. TCE, or trichloroethene, is a widely ...
... 2012: Element Six, the world leader in synthetic ... of Warwick,s Departments of Chemistry and Physics, have ... properties of metal-like boron-doped synthetic diamond. The research ... properties while retaining the full strength and durability ...
Cached Biology News:Mining cleanup benefits from Texas A&M expertise 2Mining cleanup benefits from Texas A&M expertise 3Palladium-gold nanoparticles clean TCE a billion times faster than iron filings 2Synthetic diamond steps closer to next generation of high performance electrochemical applications 2Synthetic diamond steps closer to next generation of high performance electrochemical applications 3
(Date:7/11/2014)... July 11, 2014 /PRNewswire-iReach/ -- Maxim Peptide, a website ... are used solely in scientific experiments, is currently celebrating ... in business, Maxim Peptide, which was created by the ... new and updated website that now features a special ... been updated with fascinating articles about peptide research, including ...
(Date:7/11/2014)... 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) ... (eslicarbazepine acetate) for use as a once-daily adjunctive therapy ... epilepsy who are not satisfactorily controlled with conventional therapy. ... patients under 18 years of age. ... and according to Epilepsy Canada, it affects 0.6% of ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Deep ... Century Medicine Forum on ‘Commercialising Longevity Research’ and ... entrepreneurs to the London Bioscience Innovation Center for ... Foundation and Aging Analytics Ltd. The meeting highlighted ... in translational research for age-related disease, as well ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 OMICS Group’s ... techniques during 18-20 August, 2014 at Double Tree by ... the recent developments in Analytical & Bioanalytical research methods ... , Speaking on this occasion, Dr. Srinubabu Gedela, MD ... Acta conference is a remarkable one in bringing a ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... DIEGO, Dec. 15, 2010 Ocera Therapeutics, Inc. ... evaluating the safety and pharmacokinetics of OCR-002 (ornithine ... liver cirrhosis.  OCR-002 recently received Orphan Drug status ... Food and Drug Administration for the treatment of ...
... , This release is available in ... scientists have identified the primary site where the virus ... This discovery could lead to development of new ... contagious and sometimes fatal viral disease of cloven-hoofed animals ...
... small cabinet the size of a dorm refrigerator in one of ... bottles under the cool light of red, blue and green LEDS. ... of champions. The soup is colored by a strain of ... produced by their nearest competitorsin part because of their unique genetic ...
Cached Biology Technology:Ocera Therapeutics Completes First in Human Studies with OCR-002 for the Treatment of Hyperammonemia and Hepatic Encephalopathy 2Ocera Therapeutics Completes First in Human Studies with OCR-002 for the Treatment of Hyperammonemia and Hepatic Encephalopathy 3USDA scientists discover how foot-and-mouth disease virus begins infection in cattle 2Champion hydrogen-producing microbe 2Champion hydrogen-producing microbe 3Champion hydrogen-producing microbe 4
This issue concentrated on the purification of proteins for specific purposes (i.e. large-scale purification, purification for therapeutic use, etc.)...
Edited by D.M. Gersten (1996) Provides comprehensive descriptions of the techniques available for analytical gel electrophoresis of proteins and offers clear step-by-step protocols for all of the m...
... M. Walker (1996) • This book ... for studying proteins and peptides. Each ... step-by-step instruction, timesaving troubleshooting tips, alternative ... of reagents and suppliers. Topics covered ...
...
Biology Products: